Akromegali: nye behandlingsprincipper

Jens Otto Lunde Jørgensen; Ulla Friis Feldt-Rasmussen; Marianne Andersen; Lars Østergård Kristensen; Peter Laurberg; Jørgen Weeke

Akromegali: nye behandlingsprincipper

Jens Otto Lunde Jørgensen, Ulla Friis Feldt-Rasmussen, Marianne Andersen, Lars Østergård Kristensen, Peter Laurberg, Jørgen Weeke

1 Citationer (Scopus)

Abstract

Acromegaly is a rare condition usually caused by a GH secreting pituitary tumor. Rigorous control of the disease is important in order to bring the mortality rate on level with that of the background population. Surgery is first choice, and it is sufficient in 50-60% of the patients. Treatment with a somatostatin analogue is second choice and normalises GH hypersecretion in 60% of the patients; tumor shrinkage occurs in 30%. A newly developed GH receptor antagonist, pegvisomant, seems to offer complete suppression of GH activity in most patients and also improves glucose tolerance. The disadvantages of pegvisomant include lack of suppression of tumor activity and a high cost.

Bidragets oversatte titel	Acromegaly: new principles for treatment
Originalsprog	Dansk
Tidsskrift	Ugeskrift for Laeger
Vol/bind	169
Udgave nummer	10
Sider (fra-til)	904-6
Antal sider	3
ISSN	0041-5782
Status	Udgivet - 5 mar. 2007
Udgivet eksternt	Ja

Emneord

Acromegaly/drug therapy
Dopamine Agonists/therapeutic use
Human Growth Hormone/analogs & derivatives
Humans
Somatostatin/analogs & derivatives

Citationsformater

@article{aca0c705637b48b9b5dfcccbc600d7e4,

title = "Akromegali: nye behandlingsprincipper",

abstract = "Acromegaly is a rare condition usually caused by a GH secreting pituitary tumor. Rigorous control of the disease is important in order to bring the mortality rate on level with that of the background population. Surgery is first choice, and it is sufficient in 50-60% of the patients. Treatment with a somatostatin analogue is second choice and normalises GH hypersecretion in 60% of the patients; tumor shrinkage occurs in 30%. A newly developed GH receptor antagonist, pegvisomant, seems to offer complete suppression of GH activity in most patients and also improves glucose tolerance. The disadvantages of pegvisomant include lack of suppression of tumor activity and a high cost.",

keywords = "Acromegaly/drug therapy, Dopamine Agonists/therapeutic use, Human Growth Hormone/analogs & derivatives, Humans, Somatostatin/analogs & derivatives",

author = "J{\o}rgensen, {Jens Otto Lunde} and Feldt-Rasmussen, {Ulla Friis} and Marianne Andersen and Kristensen, {Lars {\O}sterg{\aa}rd} and Peter Laurberg and J{\o}rgen Weeke",

year = "2007",

month = mar,

day = "5",

language = "Dansk",

volume = "169",

pages = "904--6",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "10",

}

TY - JOUR

T1 - Akromegali

T2 - nye behandlingsprincipper

AU - Jørgensen, Jens Otto Lunde

AU - Feldt-Rasmussen, Ulla Friis

AU - Andersen, Marianne

AU - Kristensen, Lars Østergård

AU - Laurberg, Peter

AU - Weeke, Jørgen

PY - 2007/3/5

Y1 - 2007/3/5

N2 - Acromegaly is a rare condition usually caused by a GH secreting pituitary tumor. Rigorous control of the disease is important in order to bring the mortality rate on level with that of the background population. Surgery is first choice, and it is sufficient in 50-60% of the patients. Treatment with a somatostatin analogue is second choice and normalises GH hypersecretion in 60% of the patients; tumor shrinkage occurs in 30%. A newly developed GH receptor antagonist, pegvisomant, seems to offer complete suppression of GH activity in most patients and also improves glucose tolerance. The disadvantages of pegvisomant include lack of suppression of tumor activity and a high cost.

AB - Acromegaly is a rare condition usually caused by a GH secreting pituitary tumor. Rigorous control of the disease is important in order to bring the mortality rate on level with that of the background population. Surgery is first choice, and it is sufficient in 50-60% of the patients. Treatment with a somatostatin analogue is second choice and normalises GH hypersecretion in 60% of the patients; tumor shrinkage occurs in 30%. A newly developed GH receptor antagonist, pegvisomant, seems to offer complete suppression of GH activity in most patients and also improves glucose tolerance. The disadvantages of pegvisomant include lack of suppression of tumor activity and a high cost.

KW - Acromegaly/drug therapy

KW - Dopamine Agonists/therapeutic use

KW - Human Growth Hormone/analogs & derivatives

KW - Humans

KW - Somatostatin/analogs & derivatives

M3 - Tidsskriftartikel

C2 - 17359733

SN - 0041-5782

VL - 169

SP - 904

EP - 906

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 10

ER -

Akromegali: nye behandlingsprincipper

Abstract

Emneord

Fingeraftryk

Citationsformater